Enjoying the archive? Get new posts in your inbox.
GLP1
+2
Jul 4, 2026
•
11 min read
Obesity Medicine Stopped Being a Horse Race
Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.
Cancer
+1
Jun 30, 2026
•
7 min read
The Cancer We Vaccinated Away
For five straight years, not one young woman in England has died of cervical cancer. A new Lancet analysis shows what the end of a disease looks like in real time, and why the timing could not be more painful.
GLP1
+1
Jun 27, 2026
•
10 min read
The patient barely lost weight. He got better anyway.
What the newest trial data reveal about GLP-1 medicines, and why "weight loss drug" may be the least interesting thing about them.
GLP1
+2
Jun 23, 2026
•
8 min read
Medicare Will Pay for Wegovy Now. Here's the Catch.
Starting July 1, eligible Medicare patients get Wegovy, Zepbound, or the new pill Foundayo for $50 a month. The program is real. It's transformative. And almost everything you've read about it is slightly wrong.
Obesity
+1
Jun 19, 2026
•
9 min read
Obesity Care: I Was Wrong
I argued for fixing the system from the inside. The evidence changed my mind.
GLP1
+2
Jun 16, 2026
•
9 min read
Glucagon Doesn't Win the Scale. It Wins the Liver.
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.
CV
+1
Jun 13, 2026
•
7 min read
Zero Calcium. Doubled Plaque.
A new natural-history study watched atherosclerosis grow in untreated, low-risk adults over five years — and quietly made the strongest case I’ve seen in years for treating LDL early and aggressively.
CV
+2
Jun 9, 2026
•
10 min read
The Cholesterol You Were Born With
Lp(a) drives heart attacks, strokes, and aortic stenosis in one in five people. Statins don’t touch it. Diet doesn’t move it. After six decades of therapeutic silence, 2026 is the year the verdict finally arrives — and a single gene edit may make the problem history.
